EuroEyes International Eye Clinic Gelecekteki Büyüme

Future kriter kontrolleri 4/6

EuroEyes International Eye Clinic kazanç ve gelirinin sırasıyla yıllık 26.7% ve 16.2% oranında artması tahmin edilirken, EPS'nin yıllık 3.1% oranında büyümesi bekleniyor.

Anahtar bilgiler

26.7%

Kazanç büyüme oranı

3.1%

EPS büyüme oranı

Healthcare kazanç büyümesi	19.1%
Gelir büyüme oranı	16.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

EuroEyes International Eye Clinic's (HKG:1846) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Sep 05

EuroEyes International Eye Clinic (HKG:1846) Is Reducing Its Dividend To HK$0.0489

Jun 09

EuroEyes International Eye Clinic (HKG:1846) Is Paying Out Less In Dividends Than Last Year

May 09

Earnings Tell The Story For EuroEyes International Eye Clinic Limited (HKG:1846) As Its Stock Soars 27%

May 06

EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489

Apr 25

EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489

Mar 31

What Is EuroEyes International Eye Clinic Limited's (HKG:1846) Share Price Doing?

Nov 21

Analysts Have Just Cut Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Estimates By 15%

Sep 08

EuroEyes International Eye Clinic Limited (HKG:1846) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 31

Analysts Just Made A Major Revision To Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Forecasts

Apr 25

There Are Reasons To Feel Uneasy About EuroEyes International Eye Clinic's (HKG:1846) Returns On Capital

Dec 05

EuroEyes International Eye Clinic (HKG:1846) Will Pay A Larger Dividend Than Last Year At HK$0.099

May 26

EuroEyes International Eye Clinic's (HKG:1846) Upcoming Dividend Will Be Larger Than Last Year's

May 12

EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Increased To HK$0.099

Apr 27

EuroEyes International Eye Clinic (HKG:1846) Is Increasing Its Dividend To HK$0.099

Apr 08

Slowing Rates Of Return At EuroEyes International Eye Clinic (HKG:1846) Leave Little Room For Excitement

Mar 07

Is Now An Opportune Moment To Examine EuroEyes International Eye Clinic Limited (HKG:1846)?

Jan 18

The Returns At EuroEyes International Eye Clinic (HKG:1846) Aren't Growing

Nov 02

There Are Reasons To Feel Uneasy About EuroEyes International Eye Clinic's (HKG:1846) Returns On Capital

May 20

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1846 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (HKD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,126	216	146	352	1
12/31/2025	902	151	141	254	2
12/31/2024	794	120	103	199	2
6/30/2024	736	108	111	203	N/A
3/31/2024	725	120	107	197	N/A
12/31/2023	714	131	102	192	N/A
9/30/2023	678	121	116	192	N/A
6/30/2023	641	110	129	193	N/A
3/31/2023	626	100	141	201	N/A
12/31/2022	610	89	153	209	N/A
9/30/2022	620	102	163	224	N/A
6/30/2022	629	115	172	238	N/A
3/31/2022	631	124	201	256	N/A
12/31/2021	633	134	229	273	N/A
9/30/2021	619	123	200	245	N/A
6/30/2021	605	113	171	217	N/A
3/31/2021	539	89	105	148	N/A
12/31/2020	474	66	40	78	N/A
9/30/2020	443	38	28	59	N/A
6/30/2020	412	10	16	39	N/A
3/31/2020	426	5	8	34	N/A
12/31/2019	430	-3	35	64	N/A
3/31/2019	389	23	74	91	N/A
12/31/2018	385	34	137	157	N/A
12/31/2017	347	82	N/A	83	N/A
12/31/2016	248	19	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1846 'nin tahmini kazanç büyümesi (yıllık 26.7% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 1846 şirketinin kazançlarının (yıllık 26.7% ) Hong Kong pazarından (yıllık 11.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1846 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: 1846 şirketinin gelirinin (yıllık 16.2% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1846 şirketinin gelirinin (yıllık 16.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1846 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 12:33
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

EuroEyes International Eye Clinic Limited 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Wai Chak Yuen	BOCI Research Ltd.
Yichi Zhang	China International Capital Corporation Limited
Yue-Kwong Lui	Jefferies LLC

EuroEyes International Eye Clinic Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates fall by 53%

Price target decreased by 23% to HK$7.26

Consensus revenue estimates fall by 15%

Price target increased by 13% to HK$7.16

Consensus revenue estimates increase by 25%, EPS downgraded

Price target decreased to HK$5.05

Recent updates

Consensus EPS estimates fall by 53%

Upcoming dividend of HK$0.035 per share

EuroEyes International Eye Clinic's (HKG:1846) Sluggish Earnings Might Be Just The Beginning Of Its Problems

EuroEyes International Eye Clinic Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 18 October 2024

EuroEyes International Eye Clinic Limited to Report First Half, 2024 Results on Aug 29, 2024

EuroEyes International Eye Clinic (HKG:1846) Is Reducing Its Dividend To HK$0.0489

Euroeyes International Eye Clinic Limited Declares the Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of HK$0.049 per share

EuroEyes International Eye Clinic (HKG:1846) Is Paying Out Less In Dividends Than Last Year

Earnings Tell The Story For EuroEyes International Eye Clinic Limited (HKG:1846) As Its Stock Soars 27%

Investor sentiment improves as stock rises 16%

EuroEyes International Eye Clinic Limited, Annual General Meeting, Jun 06, 2024

EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489

VP of Denmark & Executive Director recently bought HK$835k worth of stock

EuroEyes International Eye Clinic's (HKG:1846) Dividend Will Be Reduced To HK$0.0489

EuroEyes International Eye Clinic Limited Proposes Final Ordinary Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024

New minor risk - Financial data availability

EuroEyes International Eye Clinic Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

VP of Denmark & Executive Director recently bought HK$478k worth of stock

Price target decreased by 23% to HK$7.26

Founder recently bought HK$215k worth of stock

What Is EuroEyes International Eye Clinic Limited's (HKG:1846) Share Price Doing?

Investor sentiment improves as stock rises 21%

Founder recently bought HK$448k worth of stock

Analysts Have Just Cut Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Estimates By 15%

Consensus revenue estimates fall by 15%

Founder recently bought HK$54k worth of stock

Upcoming dividend of HK$0.051 per share at 2.1% yield

First half 2023 earnings released: EPS: HK$0.20 (vs HK$0.14 in 1H 2022)

EuroEyes International Eye Clinic Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 28 September 2023

EuroEyes International Eye Clinic Limited to Report First Half, 2023 Results on Aug 29, 2023

EuroEyes International Eye Clinic Limited (HKG:1846) Shares Could Be 24% Below Their Intrinsic Value Estimate

Now 20% undervalued after recent price drop

Upcoming dividend of HK$0.063 per share at 1.3% yield

Now 23% undervalued after recent price drop

Price target increased by 13% to HK$7.16

Analysts Just Made A Major Revision To Their EuroEyes International Eye Clinic Limited (HKG:1846) Revenue Forecasts

Now 22% undervalued after recent price drop

Consensus revenue estimates increase by 25%, EPS downgraded

Full year 2022 earnings released: EPS: HK$0.27 (vs HK$0.41 in FY 2021)

Founder recently bought HK$910k worth of stock

Founder recently bought HK$4.4m worth of stock

Euroeyes International Eye Clinic Limited Announces Resignation of Ralf-Christian Lerche as an Executive Director

Founder recently bought HK$111k worth of stock

Founder recently bought HK$90k worth of stock

There Are Reasons To Feel Uneasy About EuroEyes International Eye Clinic's (HKG:1846) Returns On Capital

Price target decreased to HK$5.05

Less than half of directors are independent

Founder recently bought HK$297k worth of stock

Founder recently bought HK$345k worth of stock

Founder recently bought HK$364k worth of stock

Founder recently bought HK$1.0m worth of stock

Price target decreased to HK$10.62

Founder recently bought HK$546k worth of stock

Founder recently bought HK$474k worth of stock

Founder recently bought HK$976k worth of stock

Founder recently bought HK$1.3m worth of stock

Founder recently bought HK$538k worth of stock

First half 2022 earnings released: EPS: HK$0.14 (vs HK$0.20 in 1H 2021)

EuroEyes International Eye Clinic Limited to Report First Half, 2022 Results on Aug 24, 2022

Founder recently bought HK$600k worth of stock

Founder recently bought HK$383k worth of stock

Euroeyes International Eye Clinic Limited Appoints Dan Zoltan Reinstein as Executive Director

Investor sentiment improved over the past week

Euroeyes International Eye Clinic Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.099 per share

EuroEyes International Eye Clinic (HKG:1846) Will Pay A Larger Dividend Than Last Year At HK$0.099

Founder recently bought HK$1.3m worth of stock

EuroEyes International Eye Clinic's (HKG:1846) Upcoming Dividend Will Be Larger Than Last Year's